Rabies virus is a neurotropic virus in the Rhabdoviridae family. It is bullet-shaped and enveloped with glycoprotein spikes. It has a single-stranded RNA genome that encodes five proteins. Rabies virus is highly resistant in the environment and transmitted through bites from infected animals. It travels through peripheral nerves to the central nervous system. Clinical features include an incubation period of 1-3 months followed by neurological symptoms such as hyperactivity, paralysis, and eventually coma. Laboratory diagnosis involves virus isolation, antigen detection, antibody detection, and PCR. Prophylaxis includes vaccination both pre- and post-exposure, as well as administration of rabies immunoglobulin.
all about rabies
epidemiology of rabies,
pathogenesis of rabies,
clinical features of rabies,
treatment of rabies,
prevention of rabies,
rabies virus,
post exposure prophylaxis,
rabies in dogs
all about rabies
epidemiology of rabies,
pathogenesis of rabies,
clinical features of rabies,
treatment of rabies,
prevention of rabies,
rabies virus,
post exposure prophylaxis,
rabies in dogs
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
3. Morphology
•Shape- Bullet shaped, one end round other end
concave or planer
Knob like surface projections all over the surface
except on concave end
Below the envelop has matrix (M) protein layer –
may project out as bleb from concave end
•Size- length varies
•Enveloped RNA Virus
5. Peplomer/spike- Present on surface,
Glycoprotein in nature,9 nm long
Haemagglutinating Property- optimal with goose
cells at 0-40cpH 6.2
Nucleocapsid-165x50nm,30-35 coils
6.
7. Resistance-
highly resistant against dryness, cold
Infective for many wks in cadaver.
Sensitive to lipid solvent-chloroform, acetone,
ether. Ethanol, iodine,soap,phenol,formalin,beta
propiolactone, sunlight, UV
8.
9. • Street virus- isolated from natural human/
animal infection
• Produce fatal encephalitis- after long
incubation period1-12days
• Produced Negri bodies
• Fixed virus- obtained by several intracerebral
passage in rabbits
• More neurotropic- short incubation period
• Negri bodies usually not demonstrated
10. Pathogenesis
Highly neurotropic
•Attachment of virus to host cell after inoculation
Via glycoprotein spike
Site of attachment- nicotinic acetylcholine binding
site of plasma mem. of muscle
cell (myotubule)
•Enters peripheral nerve
(time required depends upon conc. &site of bite)
11. After sufficient multiplication cross myoneural
junction- entry in CNS
(through myelinated sensory and motor axon
terminal)
•Once enter CNS infection cannot be halted by
vaccination
Passage to CNS occurs axonally through
axoplasmic flow (12-24mm/day)until it reaches
next neuron at the level of spinal cord
12. •First symptom appears when virus multiplies in
spinal ganglion- paresthesis or pain
•Rapid dissemination of virus in CNS(200-400mm/day)
•(Initially cell- cell transfer of bare nucleocapsid
•Later free passage of virus in intracellular space)
•Development of progressive encephalitis
•Centrifugal spread of virus along peripheral
nerve throughout the body – most notably
salivary gland
13. Clinical features
Incubation period- 20 days to 3yrs.mean (1-3mo)
Route of entry- bite of rabid animal- dog
(Inhalation of virus aerosols generated in bat
caves,rarely through scratch)
Four stages- prodromal, acute neurologic , coma,
complication, death
Prodromal- Usually nonspecific symptoms-
malaise, fever chills, nausea, vomiting
diarrhea, headache, anxiety,
apprehension, irritability.(lasts for 2-10days)
14. Acute neurologic phase-
Two forms- 1. furious encephalitis (>80%)
2. paralytic (dumb) form (20%)
Furious encephalitis- Hyperactivity, disorientation,
hallucination or bizarre behavior. Hyperactivity
becomes intermittent. Signs of autonomic
instability-often prominent (hyperthermia, tachycardia,
hypertension) Hydrophobia- Attempt of drinking
follows severe spasm of pharynx, larynx.
Aerophobia-due to exaggerated respiratory
irritant reflexes
•Fever, muscle fasciculation, hyperventilation, focal convulsion
15. Paralytic (dumb) rabies- initially patient is
mentally intact. No hyperactivity as in furious type
Fever, headache frequently present
Paralysis- maximal at bitten extremity,may be
diffuse& symmetric or may be ascending type
neck stiffness
Mental condition gradually deteriorate from
confusion to disorientation, stupor & finally coma
•Last for 2-7 days
•Abrupt death due to respiratory or cardiac arrest
16. Coma- develops in about 10 days after onset of
symptoms
Lasts for few hours to month
Complications- Neurologic, Pitutary, Pulmonary
Cardiovascular, other
Death due to respiratory or cardiac failure
17. Laboratory diagnosis
Specimens-
Antimortem- Saliva, CSF, Corneal impression
smear, biopsy from neck( above
hair line) , facial skin biopsy
Postmortem- CSF, brain biopsy.
1.Isolation of virus-
a. intracerebral inoculation in the mice
observe brain tissue for inclusion bodies on
28th day
18. b. Tissue culture- cell lines used-WI 38, BHK21 --
detection of virus by immunofluorescence-
Results available in 2-4days
2. Demonstration of viral antigen-
By immunofluorescence
3. Detection of inclusion bodies-(Negri bodies)
Intracytoplasmic, oval/ round, purple-pink
characteristic basophilic inner grannules
Size- 3-27 mm, eosinophilic
Stain- Seller’s technique, immunofluorescence
19. Common- hippocampus, horns of Ammon
Purkingie’s cells of cerebellum
20% of absent
Demonstration of Antibodies
Neutralising antibodies- high titre- in CSF
appear around 6th day
2- 25 times more than serum titre
Detection of Nucleic acid- RT PCR
20. Prophylaxis-
Preexposure- lab workers
Post exposure- local treatment, vaccination,
hyperimmune sera
Local treatment- soap and water.
Treatment with cetavalon- quaternary ammonium
compound,tincture iodine, alcohol
In severe wound- antirabic serum –infiltrated
around the wound. Excision of damaged tissue
Anti-titanus& antibiotics
21. Vaccines- 2 types
Neural-
1.semple vaccine- 5% suspension of infected brain.
Inactivated by 5%Phenol
2.Beta propiolactone vaccine(BPL)- 5%
Suspension of infected brain inactivation by BPL –
mainly Indian manufacturing
3.Infant brain vaccine- sucking mice brain.Inactivation
by UV radiation, BPL or phenol
22. Vaccination Schedule
Semple vaccine BPL vaccine
Class I 2ml x 7days 2ml x 7days
Class II 5ml x 14 days 3ml x 10days
Class III 10ml x 14 days 5ml x 10days
Booster required for BPL vaccine for Class II& III
Class II- 1 dose 3wks after last 10th injection
ClassIII- 2 doses- 1 7days after 10th injection 2nd 2wks
after 1st booster
23. Non-neural-
1.Duck egg vaccine- discontinued
2.Tissue culture- fixed virus grown in HDCS,WI-38,
MRC-5Inactivation by BPL-no side
effect, highly antigenic
3. Chick embryo vaccine
a.Low egg passage- 40-50 passages- live attenuated-
use for dogs
b.High egg passage- about 180 passages- live
attenuated-use for cattle, cat
Subunit vaccine- Surface glycoprotein G – cloned-
recombinant- under trial.
24. cell culture Vaccine schedule
•Same for children and adult
•Same for all three available vaccines
•Pre-exposure-
•Three doses- 0,7,21 dose-1ml Route- IM
•Booster after 1 yr & then every 5 yr.
25. Post exposure prophylaxis
• Local treatment of wound
• Passive immunization-Hyperimmune sera
• Active immunization- vaccination
• Cell culture vaccine- 1.oml- IM- adult- deltoid
• Children-anteriolateral aspect of thigh
• Five doses-
• 0,3,7,14,30 optional 90- protective for 5 yrs- during
this period 1or2 doses required on further exposure
26. Passive immunisation- Hyperimmune serum
1.Human antirabies immunoglobulin- (HRIG)
20 IU/kg body wt- half dose is infiltrated
locally in wound and other half administered- IM
•Should not be given to individual who had prior
active immunization
2.Equine/ horse hyperimmune serum-(ERIG)
40 IU /kg body wt
risk of hypersensitivity